Literature DB >> 17571171

Resource implications for a population-based colorectal cancer screening program in Canada: a study of the impact on colonoscopy capacity and costs in London, Ontario.

Agatha Lau1, James C Gregor.   

Abstract

OBJECTIVE: Cancer Care Ontario has recommended a population-based colorectal cancer (CRC) screening program using fecal occult blood testing. Patients who test positive should undergo further investigation, preferably colonoscopy. So far, no studies have been performed to quantify the costs or demands on the health care system at the community level. The number of consultations, colonoscopies and polypectomies, and the corresponding direct medical costs generated by the CRC screening program, between 2006 and 2015 in London, Ontario, were estimated using a decision analysis model in comparison with the population health model.
METHODS: A faxed survey study was conducted to examine the current CRC screening practice among family physicians in London. Data from the survey and randomized studies were applied to a decision analysis model, which simulated the steps involved in population-based biennial and annual CRC screening between 2006 and 2015. The number of consultations, colonoscopies and polypectomies, and their associated costs were calculated.
RESULTS: For a cohort population of 140,000, between 50 and 74 years of age, in 2006 to 2015, it is estimated that an average of 412 consultations, 463 colonoscopies and 174 polypectomies will be performed per 100,000 screen eligible population per year in biennial screening, and double in annual screening, reflecting an average of 8.7% or 17.6% increase annually in outpatient colonoscopies, respectively, compared with 2003. A mean of $285,000 or $562,000 per year would be required to support the extra consultation and endoscopic procedures generated by the biennial or annual screening.
CONCLUSION: Population-based fecal occult blood testing screening for CRC appears to be a manageable strategy if a modest increase in endoscopic resources is allocated.

Entities:  

Mesh:

Year:  2007        PMID: 17571171      PMCID: PMC2658120          DOI: 10.1155/2007/810941

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  12 in total

1.  Colorectal cancer screening. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2001-07-24       Impact factor: 8.262

2.  Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.

Authors:  Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex
Journal:  CA Cancer J Clin       Date:  2006 May-Jun       Impact factor: 508.702

3.  Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380.

Authors:  D A Lieberman; D G Weiss; J H Bond; D J Ahnen; H Garewal; G Chejfec
Journal:  N Engl J Med       Date:  2000-07-20       Impact factor: 91.245

4.  POHEM--a framework for understanding and modelling the health of human populations.

Authors:  M C Wolfson
Journal:  World Health Stat Q       Date:  1994

5.  Screening for colorectal cancer: the cost to find an advanced adenoma.

Authors:  J S McGrath; T P Ponich; J C Gregor
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

6.  Randomised study of screening for colorectal cancer with faecal-occult-blood test.

Authors:  O Kronborg; C Fenger; J Olsen; O D Jørgensen; O Søndergaard
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

7.  Potential impact of population-based colorectal cancer screening in Canada.

Authors:  William M Flanagan; Christel Le Petit; Jean-Marie Berthelot; Kathleen J White; B Ann Coombs; Elaine Jones-McLean
Journal:  Chronic Dis Can       Date:  2003

8.  Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.

Authors:  Sidney Winawer; Robert Fletcher; Douglas Rex; John Bond; Randall Burt; Joseph Ferrucci; Theodore Ganiats; Theodore Levin; Steven Woolf; David Johnson; Lynne Kirk; Scott Litin; Clifford Simmang
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

9.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

Authors:  J S Mandel; J H Bond; T R Church; D C Snover; G M Bradley; L M Schuman; F Ederer
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

10.  A population-based estimate of the extent of colorectal cancer screening in Ontario.

Authors:  Linda Rabeneck; Lawrence F Paszat
Journal:  Am J Gastroenterol       Date:  2004-06       Impact factor: 10.864

View more
  4 in total

1.  Colonoscopy after CT-diagnosed acute diverticulitis: Is it really necessary?

Authors:  George Ou; Greg Rosenfeld; Jacqueline Brown; Nathan Chan; Thomas Hong; Howard Lim; Brian Bressler
Journal:  Can J Surg       Date:  2015-08       Impact factor: 2.089

2.  Regional variations and associations between colonoscopy resource availability and colonoscopy utilisation: a population-based descriptive study in Ontario, Canada.

Authors:  Colleen Webber; Jennifer A Flemming; Richard Birtwhistle; Mark Rosenberg; Patti A Groome
Journal:  BMJ Open Gastroenterol       Date:  2022-06

3.  Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer.

Authors:  Shawn A Ritchie; Jon Tonita; Riaz Alvi; Denis Lehotay; Hoda Elshoni; Su- Myat; James McHattie; Dayan B Goodenowe
Journal:  Int J Cancer       Date:  2012-06-26       Impact factor: 7.396

Review 4.  National Data Analysis and Systematic Review for Human Resources for Cervical Cancer Screening in Japan.

Authors:  Chisato Hamashima; Seiju Sasaki; Satoyo Hosono; Keika Hoshi; Takafumi Katayama; Teruhiko Terasawa
Journal:  Asian Pac J Cancer Prev       Date:  2021-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.